Segui
Giuseppe Luigi Banna
Giuseppe Luigi Banna
Portsmouth Hospitals NHS Trust
Email verificata su medicareonlus.com
Titolo
Citata da
Citata da
Anno
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ...
The Lancet Oncology 21 (7), 914-922, 2020
6462020
Gut microbiota and cancer: from pathogenesis to therapy
S Vivarelli, R Salemi, S Candido, L Falzone, M Santagati, S Stefani, ...
Cancers 11 (1), 38, 2019
4672019
Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme
R Pallini, L Ricci-Vitiani, GL Banna, M Signore, D Lombardi, M Todaro, ...
Clinical Cancer Research 14 (24), 8205-8212, 2008
4182008
Anticancer oral therapy: emerging related issues
GL Banna, E CollovÓ, V Gebbia, H Lipari, P Giuffrida, S Cavallaro, ...
Cancer treatment reviews 36 (8), 595-605, 2010
2052010
TMB or not TMB as a biomarker: That is the question
A Addeo, A Friedlaender, GL Banna, GJ Weiss
Critical reviews in oncology/hematology 163, 103374, 2021
1332021
Primary results from SAUL, a multinational single-arm safety study of atezolizumab therapy for locally advanced or metastatic urothelial or nonurothelial carcinoma of theá…
CN Sternberg, Y Loriot, N James, E Choy, D Castellano, F Lopez-Rios, ...
European urology 76 (1), 73-81, 2019
1312019
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
A Friedlaender, V Subbiah, A Russo, GL Banna, U Malapelle, C Rolfo, ...
Nature reviews Clinical oncology 19 (1), 51-69, 2022
1242022
Lactobacillus rhamnosus GG: An Overview to Explore the Rationale of Its Use in Cancer
GL Banna, F Torino, F Marletta, M Santagati, R Salemi, E Cannarozzo, ...
Frontiers in pharmacology 8, 603, 2017
1162017
How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere
G Banna, A Curioni-Fontecedro, A Friedlaender, A Addeo
ESMO open 4, e000765, 2019
1152019
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
F Facchinetti, G Mazzaschi, F Barbieri, F Passiglia, F Mazzoni, R Berardi, ...
European Journal of Cancer 130, 155-167, 2020
1102020
Tumor mutation burden—from hopes to doubts
A Addeo, GL Banna, GJ Weiss
JAMA oncology 5 (7), 934-935, 2019
1052019
BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling
MO Nicoletto, M Donach, A De Nicolo, G Artioli, G Banna, S Monfardini
Cancer treatment reviews 27 (5), 295-304, 2001
1042001
KRAS as a druggable target in NSCLC: Rising like a phoenix after decades of development failures
A Friedlaender, A Drilon, GJ Weiss, GL Banna, A Addeo
Cancer treatment reviews 85, 101978, 2020
1012020
Chemotherapy in combination with immune checkpoint inhibitors for the first-line treatment of patients with advanced non-small cell lung cancer: a systematic review andá…
A Addeo, GL Banna, G Metro, M Di Maio
Frontiers in oncology 9, 264, 2019
962019
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumabá…
A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ...
Journal for immunotherapy of cancer 9 (4), 2021
932021
New emerging targets in cancer immunotherapy: the role of TIM3
A Friedlaender, A Addeo, G Banna
ESMO open 4, e000497, 2019
882019
Treatments of AIDS-related Kaposi's sarcoma
SML Aversa, AM Cattelan, L Salvagno, G Crivellari, G Banna, ...
Critical reviews in oncology/hematology 53 (3), 253-265, 2005
842005
Immunotherapy in non-small cell lung cancer harbouring driver mutations
A Addeo, A Passaro, U Malapelle, GL Banna, V Subbiah, A Friedlaender
Cancer treatment reviews 96, 102179, 2021
782021
Next generation sequencing and genetic alterations in squamous cell lung carcinoma: where are we today?
A Friedlaender, G Banna, U Malapelle, P Pisapia, A Addeo
Frontiers in oncology 9, 166, 2019
772019
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation
A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ...
Journal for immunotherapy of cancer 8 (2), 2020
752020
Il sistema al momento non pu˛ eseguire l'operazione. Riprova pi¨ tardi.
Articoli 1–20